Results 21 to 30 of about 10,605 (184)

Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America

World Allergy Organization Journal, 2019
Background: Updated urticaria guidelines recommend that patients should be assessed for disease activity, severity, control, and quality of life at baseline and follow up.
Ivan Cherrez-Ojeda, Marcus Maurer, Jonathan A. Bernstein, Emanuel Vanegas, Miguel Felix, German D. Ramon, Luis Felipe Ensina, José Ignacio Larco Sousa, Edgar Emilio Matos Benavides, R. Cardona Villa, P. Latour Staffeld, Blanca María Morfin-Maciel, Jose Mori, Paul Wilches C, Valeria L. Mata, Annia Cherrez   +15 more
doaj   +1 more source

Cost-effectiveness of omalizumab in real world uncontrolled allergic asthma patients

Pulmonology, 2021
Objective To estimate the cost-effectiveness of omalizumab compared with standard of care in the treatment and control of severe persistent asthma, using the outcomes from the Portuguese subpopulation of the eXpeRience registry.Methods This was a ...
A. Arrobas, M.P. Barbosa, S. Rabiais, B. Vandewalle, J. Félix   +4 more
doaj   +3 more sources

Description of Baseline Characteristics of Pediatric Allergic Asthma Patients Including those Initiated on Omalizumab

Allergy & Rhinology, 2018
Background Indication of omalizumab in the United States was recently extended to include pediatric (6–11 years) uncontrolled moderate-to-severe allergic asthma patients.
Abhishek Kavati, Dominic Pilon, Benjamin Ortiz, Brandee Paknis, Ashok Vegesna, Bradd Schiffman, Maryia Zhdanava, Patrick Lefebvre, Brian Stone   +8 more
doaj   +1 more source

Efficacy and safety of omalizumab against chronic spontaneous urticaria: Real-world study from China

World Allergy Organization Journal, 2022
Background: Omalizumab is an effective treatment for chronic spontaneous urticaria (CSU) patients aged ≥12 years, but its efficacy in patients aged
Ao Wang, MD, Yuhui Yun, MM, Zhihua Wen, MM, Yingxia Gao, BS, Shuzhen Qi, MD, Yu Zhang, MD, Yunsheng Liang, MD, Xu Yao, MD   +7 more
doaj   +1 more source

Development of Assay for Determining Free IgE Levels in Serum from Patients Treated with Omalizumab

Allergology International, 2014
Background: Omalizumab, a monoclonal anti-IgE antibody, is currently indicated for the treatment of moderate-to-severe allergic asthma. To measure active IgE levels in sera from patients treated with omalizumab, the IgE subfraction in complex with ...
Reiko Ito, Yasuhiro Gon, Satoshi Nunomura, Ryo Atsuta, Norihiro Harada, Tomohiro Hattori, Shuichiro Maruoka, Yoshimichi Okayama, Chisei Ra, Shu Hashimoto   +9 more
doaj   +1 more source

Efficacy of Biologics in Aspirin Exacerbated Respiratory Disease. [PDF]

Clin Transl Allergy
ABSTRACT Background Aspirin‐exacerbated respiratory disease (AERD), also termed nonsteroidal anti‐inflammatory drug exacerbated respiratory disease (NERD), is characterized by asthma, chronic rhinosinusitis with nasal polyposis, and hypersensitivity to cyclooxygenase‐1 inhibitors, frequently resulting in severe, treatment‐refractory airway disease ...
Priessnitz JK, Hagopian A, Patev AJ, Han JK, Lam KK.   +4 more
europepmc   +2 more sources

Omalizumab and IgE in the Control of Severe Allergic Asthma

Frontiers in Pharmacology, 2022
Omalizumab, a human immunoglobulin (Ig)G1 antibody against IgE, is a therapeutic agent for bronchial asthma. The Global Initiative for Asthma guidelines indicate that the use of omalizumab should be considered as an option in step 5 of treatment for ...
Yasuhiro Gon, Shuichiro Maruoka, Kenji Mizumura   +2 more
doaj   +1 more source

A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad

Monaldi Archives for Chest Disease, 2020
Omalizumab proved to be very effective in improving control of severe atopic asthma. Many small-sized studies suggested a potential role for omalizumab in the management of aspirin-exacerbated respiratory disease. The aim of this study is to describe the
Paolo Cameli, Miriana d'Alessandro, Laura Bergantini, Elena Silvestri, Arianna Romaldi, Giacomo Emmi, Paola Parronchi, Elena Bargagli   +7 more
doaj   +1 more source

Solar Urticaria: An Ambispective Study in a Long-term Follow-up Cohort with Emphasis on Therapeutic Predictors and Outcomes

Acta Dermato-Venereologica
Solar urticaria is a rare photodermatosis with several unknown pathogenic, clinical and therapeutic aspects. This study analysed the clinical and therapeutic features of a long-term follow-up solar urticaria cohort, with a focus on omalizumab management ...
David Pesqué, Andrea Ciudad, Evelyn Andrades, Dulce Soto, Ramon Gimeno, Ramon M. Pujol, Ana M. Giménez-Arnau   +6 more
doaj   +1 more source

Tezepelumab in Chinese Patients With Severe Chronic Rhinosinusitis With Nasal Polyps: A Prespecified Subgroup Analysis of the Phase 3 WAYPOINT Trial

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) in Chinese patients often exhibits a mixed Type 1/2/3 inflammatory phenotype (63%), potentially impacting the efficacy of biologics targeting Type 2 inflammation. This prespecified subgroup analysis of WAYPOINT (NCT04851964) evaluated the efficacy and safety of tezepelumab in Chinese
Li Hu, Houyong Li, Xicai Sun, Quan Liu, Yu Xu, Jiangang Fan, Andrew Foster, Claudia Chen, Yun Chon, Dehui Wang   +9 more
wiley   +1 more source